Bristol Myers Squibb Company’s melanoma drug Opdualag (nivolumab plus relatlimab) has received a positive reimbursement opinion from England’s health technology assessment (HTA) body, NICE, less than two weeks after the drug was authorized for use by the medicines regulator, the MHRA.
BMS Praises England’s New HTA Process As Opdualag Gets Funding For Melanoma
England’s health technology assessment body, NICE, and the medicines regulator, the MHRA, are “leading the way” in making innovation available to patients and ensuring an efficient and proportionate use of resources, according to BMS.
More from Market Access
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
More from Pink Sheet
• By
One CDRH employee said the cuts already are having a major effect on morale.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.